专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011003557A8 A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT 审中-公开
标题翻译：双重特异性抗体复合物和联合治疗或诊断代谢物的二氢吉他宁
公开(公告)号：WO2011003557A8
公开(公告)日：2012-01-26
申请号：PCT/EP2010004051
申请日：2010-07-05
申请人： HOFFMANN LA ROCHE , BRINKMANN ULRICH , CROASDALE REBECCA , LAU WILMA , GEORGES GUY , HAAS ALEXANDER , HOFFMANN EIKE , METZ SILKE , MUNDIGL OLAF , SCHEUER WERNER , STRACKE JAN OLAF
发明人： BRINKMANN ULRICH , CROASDALE REBECCA , LAU WILMA , GEORGES GUY , HAAS ALEXANDER , HOFFMANN EIKE , METZ SILKE , MUNDIGL OLAF , SCHEUER WERNER , STRACKE JAN OLAF
IPC分类号： A61K39/395 , A61K47/48 , C07K16/16 , C07K16/28 , C07K16/32 , C07K16/44 , C07K16/46 , C12N15/113
CPC分类号： C07K16/44 , A61K31/704 , A61K39/39533 , A61K47/6879 , A61K47/6897 , A61K49/0045 , A61K49/0058 , A61K2039/505 , B82Y5/00 , C07K16/16 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K2317/24 , C07K2317/31 , C07K2317/51 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/77 , C07K2317/92 , C07K2319/30 , C12N15/111 , C12N15/1138 , C12N2310/14 , C12N2310/3513 , C12N2320/32 , A61K2300/00
摘要： The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及a）双特异性抗体和针对靶蛋白的抗体片段的复合物，以及b）与治疗或诊断试剂缀合的地高辛素，其生产方法，它们作为治疗或诊断试剂递送平台的用途，含有所述抗体的药物组合物及其用途。

2. 发明申请

WO2010040508A1 BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES 审中-公开
标题翻译：双相抗VEGF /抗ANG-2抗体
公开(公告)号：WO2010040508A1
公开(公告)日：2010-04-15
申请号：PCT/EP2009007182
申请日：2009-10-07
申请人： HOFFMANN LA ROCHE , BAEHNER MONIKA , BRINKMANN ULRICH , GEORGES GUY , GRIEP REMKO ALBERT , IMHOF-JUNG SABINE , KAVLIE ANITA , KETTENBERGER HUBERT , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHEFER WOLFGANG , SCHANZER JUERGEN MICHAEL , SCHEUER WERNER , SEEBER STEFAN , THOMAS MARKUS
发明人： BAEHNER MONIKA , BRINKMANN ULRICH , GEORGES GUY , GRIEP REMKO ALBERT , IMHOF-JUNG SABINE , KAVLIE ANITA , KETTENBERGER HUBERT , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHEFER WOLFGANG , SCHANZER JUERGEN MICHAEL , SCHEUER WERNER , SEEBER STEFAN , THOMAS MARKUS
IPC分类号： C07K16/22 , A61K39/395 , C07K14/00 , C07K16/46 , C07K19/00
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及针对人VEGF和针对人ANG-2的双特异性抗体，其制备方法，含有所述抗体的药物组合物及其用途。

3. 发明申请

WO2010040508A8 BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES 审中-公开
标题翻译：双相抗VEGF /抗ANG-2抗体
公开(公告)号：WO2010040508A8
公开(公告)日：2011-02-24
申请号：PCT/EP2009007182
申请日：2009-10-07
申请人： HOFFMANN LA ROCHE , BAEHNER MONIKA , BRINKMANN ULRICH , GEORGES GUY , GRIEP REMKO ALBERT , IMHOF-JUNG SABINE , KAVLIE ANITA , KETTENBERGER HUBERT , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHAEFER WOLFGANG , SCHANZER JUERGEN MICHAEL , SCHEUER WERNER , SEEBER STEFAN , THOMAS MARKUS
发明人： BAEHNER MONIKA , BRINKMANN ULRICH , GEORGES GUY , GRIEP REMKO ALBERT , IMHOF-JUNG SABINE , KAVLIE ANITA , KETTENBERGER HUBERT , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHAEFER WOLFGANG , SCHANZER JUERGEN MICHAEL , SCHEUER WERNER , SEEBER STEFAN , THOMAS MARKUS
IPC分类号： C07K16/22 , A61K39/395 , C07K14/00 , C07K16/46 , C07K19/00
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及针对人VEGF和针对人ANG-2的双特异性抗体，其制备方法，含有所述抗体的药物组合物及其用途。

4. 发明申请

WO2010069532A8 ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 审中-公开
标题翻译：抗体人类抗体2
公开(公告)号：WO2010069532A8
公开(公告)日：2012-05-10
申请号：PCT/EP2009008930
申请日：2009-12-14
申请人： HOFFMANN LA ROCHE , BRINKMANN ULRICH , GRIEP REMKO ALBERT , KALUZA KLAUS , KAVLIE ANITA , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHEUER WERNER
发明人： BRINKMANN ULRICH , GRIEP REMKO ALBERT , KALUZA KLAUS , KAVLIE ANITA , KLEIN CHRISTIAN , REGULA JOERG THOMAS , SCHEUER WERNER
IPC分类号： C07K16/22 , A61K39/395 , A61P35/00
CPC分类号： C07K16/22 , A61K39/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C12N15/85
摘要： The present invention relates to antibodies against human Angiopoietin 2 (anti- ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
摘要翻译：本发明涉及抗人血管生成素2（抗ANG-2抗体）的抗体，其生产方法，含有所述抗体的药物组合物及其应用。

5. 发明申请

WO2008148546A2 COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL 审中-公开
标题翻译：第一个非标记的单克隆抗体与肿瘤抗原结合的组合物和标记有近红色荧光标记的非交叉反应性第二单克隆抗体
公开(公告)号：WO2008148546A2
公开(公告)日：2008-12-11
申请号：PCT/EP2008004456
申请日：2008-06-04
申请人： HOFFMANN LA ROCHE , HASMANN MAX , LENZ HELMUT , SCHEUER WERNER
发明人： HASMANN MAX , LENZ HELMUT , SCHEUER WERNER
IPC分类号： C07K16/00 , A61K49/00 , A61P35/00
CPC分类号： A61K49/0058 , A61K39/39558 , A61K49/0032
摘要： This invention relates to a composition of a non-labeled monoclonal antibody binding to a tumor antigen and a second monoclonal antibody labeled with a NIR fluorescence label, binding to the same tumor antigen, wherein the first and second antibody exhibit no cross reactivity. The composition can be used for the treatment of patients suffering of solid tumors which are associated with an overexpression of such a tumor antigen. The invention further relates to a the co-administration of said first and second antibody as wells as to a method of acquiring a NIR fluorescence images of such tumors or the patients suffering from such tumors during the treatment of said patientwith such composition.
摘要翻译：本发明涉及结合肿瘤抗原的非标记单克隆抗体的组合物和用NIR荧光标记标记的第二单克隆抗体，其结合相同的肿瘤抗原，其中第一抗体和第二抗体不表现出交叉反应性。该组合物可用于治疗与这种肿瘤抗原的过表达相关的实体瘤患者。本发明还涉及所述第一和第二抗体的共同给药，关于在用这种组合物治疗所述患者期间获得这种肿瘤的近红外荧光图像或患有这些肿瘤的患者的方法。

6. 发明申请

WO2011012646A2 NON-INVASIVE IN VIVO OPTICAL IMAGING METHOD 审中-公开
标题翻译：非侵入式光学成像方法
公开(公告)号：WO2011012646A2
公开(公告)日：2011-02-03
申请号：PCT/EP2010060957
申请日：2010-07-28
申请人： HOFFMANN LA ROCHE , DOBOSZ MICHAEL , SCHEUER WERNER , STROBEL STEFFEN
发明人： DOBOSZ MICHAEL , SCHEUER WERNER , STROBEL STEFFEN
IPC分类号： A61B3/12 , A61B3/14 , A61B5/00 , A61K49/00 , G01N21/64 , G01N33/58
CPC分类号： G01N33/582 , A61B3/1241 , A61B5/0059 , A61B5/14555 , A61B5/415 , A61B5/418 , A61K49/0021 , A61K49/0032 , A61K49/0034 , G01N21/6408 , G01N21/6428
摘要： The present invention relates to a non-invasive method of determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of a fluorescent analyte which comprises a fluorescent entity and a second entity, in the blood of a subject, comprising or consisting of the steps: (a) directing excitation light of at least one predetermined wavelength onto a delineated region comprising at least a portion of the pupil of said subject, to excite the fluorescent entity, (b) receiving light emitted from said fluorescent analyte with a wavelength distinguishable from the predetermined wavelength of (a), through the eye of said subject, thereby determining the presence, quantifying the blood level, and/or monitoring or determining the blood clearance of said fluorescent analyte in the blood of said subject. The present invention further relates to a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for use in any one of the preceding methods. The present invention furthermore relates to the use of a fluorescent analyte or fluorescent label as defined in any one of the preceding claims for the preparation of a diagnostic composition which is to be employed in any one of the preceding methods. The present invention furthermore relates to a device for use in any of the methods defined herein.
摘要翻译：本发明涉及一种在受试者的血液中确定包含荧光实体和第二实体的荧光分析物的存在，量化血液水平和/或监测或确定荧光分析物的血液清除率的非侵入性方法，包括或由以下步骤组成：（a）将至少一个预定波长的激发光引导到包括所述受试者的瞳孔的至少一部分的描绘区域上，以激发荧光实体，（b）接收从所述荧光通过所述受试者的眼睛，可识别具有与（a）的预定波长区分开的波长的分析物，从而确定存在，定量血液水平，和/或监测或确定所述受试者血液中所述荧光分析物的血液清除率。本发明还涉及如前述权利要求中任一项所述的荧光分析物或荧光标记，用于上述任一方法。本发明还涉及如前述权利要求中任一项所述的荧光分析物或荧光标记物在制备用于上述任一方法的诊断组合物中的用途。本发明还涉及用于本文定义的任何方法的装置。

7. 发明专利

JP2012207036A Antibody to vascular endothelial growth factor, and tumor treatment using antibody for human epidermal growth factor receptor type 2 审中-公开
标题翻译：血管内皮生长因子的抗体和使用抗人体肿瘤生长因子受体2型的肿瘤治疗
公开(公告)号：JP2012207036A
公开(公告)日：2012-10-25
申请号：JP2012157442
申请日：2012-07-13
申请人： F Hoffmann La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： FRIESS THOMAS , HASMANN MAX , SCHEUER WERNER
IPC分类号： A61K39/395 , A61P35/00 , A61P35/04
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/22 , C07K16/3015 , C07K16/32 , C07K2317/24
摘要： PROBLEM TO BE SOLVED: To provide a pharmacological composition for reducing metastasis of cancer in a patient who has a cancer characterized by an overexpression of a HER2 receptor protein, and who has failed a prior treatment using an anti-VEGF antibody.SOLUTION: This composition contains an anti-HER2 antibody. By this drug treatment, effective amounts of the anti-HER2 antibody as well as the anti-VEGF antibody can be administrated to the patient.
摘要翻译：待解决的问题：提供一种具有以HER2受体蛋白质过表达为特征的癌症患者中的癌症转移的药理学组合物，并且其使用抗VEGF抗体的先前治疗失败了。解决方案：该组合物含有抗HER2抗体。通过该药物治疗，可以向患者施用有效量的抗HER2抗体以及抗VEGF抗体。版权所有（C）2013，JPO＆INPIT

8. 发明专利

JP2014039549A Bispecific anti-vegf/anti-ang-2 antibodies 审中-公开
标题翻译：双相抗VEGF /抗ANG-2抗体
公开(公告)号：JP2014039549A
公开(公告)日：2014-03-06
申请号：JP2013186410
申请日：2013-09-09
申请人： F. Hoffmann-La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： MONIKA BAEHNER , ULRICH BRINKMANN , GEORGES GUY , GRIEP REMKO ALBERT , IMHOF-JUNG SABINE , KAVLIE ANITA , KETTENBERGER HUBERT , KLEIN CHRISTIAN , JOERG THOMAS REGULA , SCHAEFER WOLFGANG , SCHANZER JUERGEN MICHAEL , SCHEUER WERNER , SEEBER STEFAN , MARKUS THOMAS
IPC分类号： C12N15/09 , A61K39/395 , A61P9/14 , A61P35/00 , C07K16/22 , C07K16/24 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/02 , C12P21/02
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： PROBLEM TO BE SOLVED: To provide bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and their provision and use.SOLUTION: The bispecific antibody binds specifically to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2) and comprises a first antigen-binding site that specifically binds to human VEGF and a second antigen-binding site that specifically binds to human angiopoietin-2 (ANG-2).
摘要翻译：要解决的问题：提供针对人VEGF和针对人ANG-2的双特异性抗体，其生产方法，含有所述抗体的药物组合物及其提供和用途。解决方案：双特异性抗体特异性结合人血管内皮生长因子 VEGF）和人血管生成素-2（ANG-2），并且包含特异性结合人VEGF的第一抗原结合位点和与人血管生成素-2（ANG-2）特异性结合的第二抗原结合位点。

9. 发明专利

JP2013163687A Tumor treatment by anti-vegf antibody 审中-公开
标题翻译：抗VEGF抗体的肿瘤治疗
公开(公告)号：JP2013163687A
公开(公告)日：2013-08-22
申请号：JP2013103182
申请日：2013-05-15
申请人： F Hoffmann La Roche Ag , エフ.ホフマン−ラロシュアーゲーF. Hoffmann−La Roche Aktiengesellschaft
发明人： FRIESS THOMAS , HASMANN MAX , SCHEUER WERNER
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K2039/505 , A61K2039/545 , C07K2317/76 , C07K2317/92
摘要： PROBLEM TO BE SOLVED: To provide a therapy not only for targeting at a primary tumor, but also for controlling its metastasis.SOLUTION: Provided is a therapeutic method by use of anti-VEGF antibody for a patient who suffers from a HER2 positive cancer relasped during or after treatment with an anti-HER2 antibody. Also, provided is a corresponding product.
摘要翻译：要解决的问题：不仅用于靶向原发性肿瘤而且用于控制其转移的治疗。解决方案：提供了一种通过使用抗VEGF抗体治疗患有HER2阳性癌症的患者的治疗方法在用抗HER2抗体治疗期间或之后。另外，提供了相应的产品。

10. 发明申请

WO2015051199A3 MODIFIED PSEUDOMONAS EXOTOXIN A 审中-公开
标题翻译：修饰的假单胞菌外毒素A
公开(公告)号：WO2015051199A3
公开(公告)日：2015-08-27
申请号：PCT/US2014058941
申请日：2014-10-03
申请人： US HEALTH , HOFFMANN LA ROCHE , HOFFMANN LA ROCHE
发明人： PASTAN IRA H , MAZOR RONIT , ONDA MASANORI , LEE BYUNGKOOK , NIEDERFELLNER GERHARD , IMHOF-JUNG SABINE , BRINKMANN ULRICH , SCHEUER WERNER , GEORGES GUY
IPC分类号： A61K38/16 , C07K14/21 , C07K16/12
CPC分类号： C07K16/30 , A61K31/337 , A61K38/00 , A61K39/39558 , A61K47/6803 , A61K47/6829 , A61K47/6851 , A61K47/6859 , A61K47/6871 , A61K2039/505 , C07K14/21 , C07K16/1214 , C07K16/303 , C07K16/40 , C07K2317/24 , C07K2317/55 , C07K2317/624 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/33 , C07K2319/50 , C07K2319/55 , A61K2300/00
摘要： The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
摘要翻译：本发明提供了包含具有一个或多个B细胞和/或T细胞表位取代的氨基酸序列的假单胞菌外毒素A（PE）。本发明进一步提供了相关的嵌合分子以及相关的核酸，重组表达载体，宿主细胞，细胞群和药物组合物。本发明进一步提供了治疗或预防哺乳动物癌症的方法，抑制靶细胞生长的方法，生产PE的方法以及生产嵌合分子的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式